A. Sinclair Dunlop - 18 May 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for A. Sinclair Dunlop
Issuer symbol
APLS
Transactions as of
18 May 2021
Net transactions value
-$8,558,129
Form type
4
Filing time
20 May 2021, 16:53:10 UTC
Next filing
02 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $3,315,487 -64,179 -37% $51.66 110,549 18 May 2021 See Footnote F1, F9
transaction APLS Common Stock Sale $748,188 -14,216 -13% $52.63 96,333 18 May 2021 See Footnote F2, F9
transaction APLS Common Stock Sale $1,956,893 -36,387 -38% $53.78 59,946 18 May 2021 See Footnote F3, F9
transaction APLS Common Stock Sale $1,217,893 -22,318 -37% $54.57 37,628 18 May 2021 See Footnote F4, F9
transaction APLS Common Stock Sale $62,412 -1,200 -0.37% $52.01 319,479 18 May 2021 See Footnote F5, F10
transaction APLS Common Stock Sale $555,758 -10,388 -3.3% $53.50 309,091 18 May 2021 See Footnote F6, F10
transaction APLS Common Stock Sale $43,216 -800 -0.26% $54.02 308,291 18 May 2021 See Footnote F7, F10
transaction APLS Common Stock Sale $380,600 -7,612 -2.5% $50.00 300,679 19 May 2021 See Footnote F10
transaction APLS Common Stock Sale $277,681 -5,773 -15% $48.10 31,855 20 May 2021 See Footnote F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involved a sale of shares held by MASA Life Science Ventures, LP ("MASA"). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.16 to $52.15. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) to this Form 4.
F2 The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.16 to $53.12.
F3 The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $54.15.
F4 The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.16 to $54.94.
F5 The reported transaction involved a sale of shares held by Epidarex Capital I, LP ("Epidarex"). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.00 to $52.03. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (7) to this Form 4.
F6 The reported transaction involved a sale of shares held by Epidarex. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.00 to $53.99.
F7 The reported transaction involved a sale of shares held by Epidarex. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.00 to $54.04.
F8 The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.00 to $48.50.
F9 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
F10 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.